On Tuesday, salesforce.com, inc. (NYSE:CRM)’s shares declined -0.35% to $74.52.
salesforce.com, inc. (CRM) the Customer Success Platform and world’s #1 CRM Company, recently declared that Community Cloud was named as a leader by Forrester Research in its report, The Forrester Wave™: Social Depth Platforms Q2 2015. Community Cloud received “high marks for its advanced mobile features, identity administration and extensive global support,” in addition to receiving the highest score in the market presence category.
salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship administration to various businesses and industries worldwide. The company offers enterprise cloud computing apps and platform services, counting Sales Cloud for sales force automation, which enables companies to store data, access accurate customer and prospect information, track leads and progress, forecast opportunities, and collaborate around any sale on desktop and mobile devices; Service Cloud that enables companies to connect address customers service and support needs; and Marketing Cloud, which enables companies to map customer journeys to digital marketing interactions through email, mobile, social, Web, and connected products.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)’s shares dropped -0.64% to $7.77.
Valeant Pharmaceuticals International, Inc. (VRX) (VRX) and Progenics Pharmaceuticals, Inc. (PGNX) declared that Valeant presented a New Drug Application to the U.S. Food and Drug Administration (FDA) for RELISTOR® (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
RELISTOR is a peripherally acting mu-opioid receptor antagonist specifically designed to block the constipating effects of opioid pain medications in the gastrointestinal tract. RELISTOR does not cross the blood-brain barrier, therefore relieving the distressing effects of the constipation without affecting the analgesic effect of the opioid. RELISTOR Subcutaneous Injection has been FDA approved since 2008 to treat OIC in patients with advanced illness who are receiving palliative care, and was approved in 2014 for the treatment of OIC in patients with chronic non-cancer pain.
Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The company’s primary clinical-stage product candidates comprise prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has accomplished Phase II testing in chemotherapy-practiced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has accomplished Phase II testing, in addition to acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registration trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma.
At the end of Tuesday’s trade, Quiksilver, Inc. (NYSE:ZQK)‘s shares dipped -10.31% to $0.772.
Quiksilver, Inc. (ZQK) and certain of its domestic and foreign auxiliaries reached a second amendment (the “ABL Credit Agreement Amendment”) to the Company’s existing amended and restated credit agreement, originally dated as of May 24, 2013, with, among others, the lenders named therein and Bank of America, N.A., as administrative agent, swing line lender and letter of credit issuer. The ABL Credit Agreement Amendment modified the definition of “Change of Control” to provide that where a majority of the members of the incumbent board approves new directors as a result of an actual or threatened proxy contest it will not qualify as a change of control.
Quiksilver, Inc. designs, develops, and distributes branded apparel, footwear, accessories, and related products primarily for men, women, and children. The company provides its products for various activities, counting casual and outdoor lifestyle associated with surfing, skateboarding, snowboarding, BMX and motocross, rally car, and other activities.
Allscripts Healthcare Solutions Inc (NASDAQ:MDRX), ended its Tuesday’s trading session with 0.14% gain, and closed at $14.42.
Allscripts Healthcare Solutions Inc (MDRX) client Atlantic General Hospital, located in Berlin, Maryland, U.S.A., achieved Stage 6 on the HIMSS Analytics EMR Adoption ModelSM (EMRAM) using the Allscripts Sunrise acute electronic health record (EHR).
The HIMSS Analytics EMR Adoption Model measures progress and the cumulative capabilities of EMR systems within hospitals. There are eight stages (0-7) in the HIMSS Analytics EMR Adoption Model, and 17.9% of hospitals in the HIMSS Analytics(R) Database have presently reached Stage 6. Hospitals that reach Stage 6 have established clear aims for improving safety, minimizing errors, and prioritizing IT implementations.
Allscripts Healthcare Solutions, Inc. provides clinical, financial, electronic health records (EHR), connectivity, hosting, outsourcing, analytics, patient engagement, and population health products and services in the United States and Canada. It operates in three segments: Clinical and Financial Solutions, Population Health, and Managed Services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
